2. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  3. Liposome Estrogen Receptor/ERR
  4. Paclitaxel liposome

Paclitaxel liposome  (Synonyms: Liposomal paclitaxel)

Cat. No.: HY-185373
COA
SDS
Handling Instructions Technical Support

Paclitaxel liposome (Liposomal paclitaxel) is an antitumor agent targeting Estrogen Receptor. Paclitaxel liposome binds to overexpressed Estrogen Receptor to mediate receptor-specific endocytosis, and enters cells via macropinocytosis, caveolae-dependent and clathrin-dependent endocytic pathways. Paclitaxel liposome suppresses cell viability and tumor growth, and reduces the distribution of Paclitaxel (HY-B0015) in normal tissues. Paclitaxel liposome can be used for research related to breast cancer and locally advanced esophageal squamous cell carcinoma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Paclitaxel liposome

Paclitaxel liposome 화학구조

사이즈 가격 재고 수량
10 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg   견적 받기  
500 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 Customer Validation

Paclitaxel liposome Related Antibodies

Top Publications Citing Use of Products

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms
Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Paclitaxel liposome (Liposomal paclitaxel) is an antitumor agent targeting Estrogen Receptor. Paclitaxel liposome binds to overexpressed Estrogen Receptor to mediate receptor-specific endocytosis, and enters cells via macropinocytosis, caveolae-dependent and clathrin-dependent endocytic pathways. Paclitaxel liposome suppresses cell viability and tumor growth, and reduces the distribution of Paclitaxel (HY-B0015) in normal tissues. Paclitaxel liposome can be used for research related to breast cancer and locally advanced esophageal squamous cell carcinoma[1][2].

IC50 & Target[1]

Estrogen receptor

 

In Vitro

Paclitaxel liposome (L-PTX) (0.1-5000 ng/mL; 24-72 h) exerts potent, time- and concentration-dependent cytotoxicity against human breast cancer MCF-7 cells, with an IC50 of 11.54 ng/mL after 72 h of treatment[1].
Paclitaxel liposome (5 μg/mL RhB; 1-4 h, tracked via rhodamine B labeling) is taken up by human breast cancer MCF-7 cells, with lower uptake efficiency than targeted long-acting paclitaxel liposomes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Paclitaxel liposome Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: human breast cancer MCF-7 cells
Concentration: 0.1, 1, 10, 100, 500, 1000, 5000 ng/mL
Incubation Time: 24 h; 48 h; 72 h
Result: Showed concentration- and time-dependent inhibitory effects on MCF-7 cells.
Failed to achieve an IC50 after 24 h of treatment.
Reached an IC50 of 2095 ng/mL after 48 h of treatment.
Reached an IC50 of 11 ng/mL after 72 h of treatment.
In Vivo

Paclitaxel liposome (L-PTX) (5 mg/kg; i.v.; once every 2 days; 4 consecutive administrations) inhibits MCF-7 breast tumor growth in nude mice[1].
Paclitaxel liposome (10 mg/kg; i.v.; single dose) moderately prolongs Paclitaxel (HY-B0015) circulation time in healthy ICR mice, with an elimination half-life of 2.26 h and 1.38-fold higher bioavailability than free paclitaxel[1].
The common paclitaxel liposome (L-PTX) (80-200 mg/kg; i.v.; single dose) has reduced acute toxicity in healthy ICR mice, with an LD50 of 134.46 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 16-18 g, inoculated with MCF-7 human breast cancer cells)[1]
Dosage: 5 mg/kg (based on paclitaxel content)
Administration: i.v.; once every 2 days; 4 consecutive administrations
Result: Reached mean tumor volume of 1000 mm3 after 18 days of administration.
Reached mean tumor volume of 1700 mm3 after 34 days of administration.
Showed gradual increase in body weight throughout the study period.
Appearance

Solid

Color

White to off-white

SMILES

[Paclitaxel liposome]
선적

Room temperature in continental US; may vary elsewhere.
보관

Store at 4°C, do not freeze
순도&문서
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Paclitaxel liposome Related Classifications

  • 몰농도 계산기

  • 농도 희석 계산기

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Paclitaxel liposomeLiposomal paclitaxelLiposomeEstrogen Receptor/ERRcaveolin-dependent endocytosisclathrin-dependent endocytosisbreast cancerlocally advanced esophageal squamous cell carcinomaMCF-7 cellsnude miceestrogen receptorICR micemacropinocytosisInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Paclitaxel liposome
Cat. No.:
HY-185373
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.